{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:44:14Z","timestamp":1788918254351,"version":"build-2803163510"},"reference-count":34,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"11","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82272887"],"award-info":[{"award-number":["No. 82272887"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82272887"],"award-info":[{"award-number":["No. 82272887"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">The widely accepted view that portal hypertension (PHT) is a contraindication to hepatectomy for patients with hepatocellular carcinoma (HCC) is being increasingly challenged. The long\u2010term survival outcomes and safety of partial hepatectomy versus interventional treatment using ablation with or without pre\u2010ablation transarterial chemoembolization (TACE) in patients with HBV\u2010related HCC within the Milan criteria and with clinically significant PHT were compared in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">This open\u2010label randomized clinical trial was conducted on consecutive patients with clinically PHT and hepatitis B virus (HBV)\u2010related HCC with tumors which were within the Milan criteria. These patients were randomized 1:1 to receive either partial hepatectomy or interventional treatment between December 2012 and June 2018. The primary endpoint was overall survival (OS); secondary endpoints included recurrence\u2010free survival (RFS) and therapeutic safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Each of the 2 groups had 80 patients. The 1\u2010, 3\u2010 and 5\u2010year OS rates in the partial hepatectomy group and the interventional treatment group were 95.0%, 86.2%, 69.5% versus 93.8%, 77.5%, 64.9%, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.325). The corresponding RFS rates were 78.8%, 55.0%, 46.2% versus 71.3%, 52.5%, 45.0%, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.783). The partial hepatectomy group had a higher complication rate compared to the interventional group (67.5% vs. 20%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). However, the differences were mainly in Clavien\u2010Dindo Grade I complications (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), while not significant in Grade II\/III\/IV\/V (All\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">This study shows that partial hepatectomy treatment did not meet prespecified significance for improved OS and RFS compared to interventional treatment for patients with HBV\u2010related HCC within the Milan criteria and with clinically significant PHT. However, partial hepatectomy is still a safe procedure and should be considered as a treatment option rather than a contraindication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cac2.12614","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T23:29:15Z","timestamp":1727306955000},"page":"1337-1349","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Partial hepatectomy versus interventional treatment in patients with hepatitis B virus\u2010related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinical trial"],"prefix":"10.34133","volume":"44","author":[{"given":"Yichuan","family":"Yuan","sequence":"first","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Peng","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen university","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6717-3959","authenticated-orcid":false,"given":"Yun","family":"Zheng","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiliang","family":"Qiu","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen university","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhai","family":"Zou","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Yee","family":"Lau","sequence":"additional","affiliation":[{"name":"The Chinese University of Hong Kong","place":["Hong Kong, SAR, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binkui","family":"Li","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-3683","authenticated-orcid":false,"given":"Yunfei","family":"Yuan","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"issue":"1","key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle PR","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J\u2010L, et\u00a0al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69((1)):182\u2010236.","journal-title":"J Hepatol"},{"issue":"4","key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(96)70070-7","article-title":"Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure","volume":"111","author":"Bruix J","year":"1996","unstructured":"Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia\u2010Pagan JC, et\u00a0al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996;111((4)):1018\u201022.","journal-title":"Gastroenterology"},{"issue":"6","key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/hep.510300629","article-title":"Intention\u2010to\u2010treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation","volume":"30","author":"Llovet JM","year":"1999","unstructured":"Llovet JM, Fuster J, Bruix J. Intention\u2010to\u2010treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30((6)):1434\u201040.","journal-title":"Hepatology"},{"issue":"3","key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig M","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer\u2010F\u00e0brega J, Burrel M, Garcia\u2010Criado \u00c1, et\u00a0al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76((3)):681\u201093.","journal-title":"J Hepatol"},{"issue":"3","key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/hep.27703","article-title":"Should surgery be carried out in patients with hepatocellular carcinoma with portal hypertension?","volume":"62","author":"Yang T","year":"2015","unstructured":"Yang T, Lau WY, Zhang H, Wu M, Shen F. Should surgery be carried out in patients with hepatocellular carcinoma with portal hypertension? Hepatology. 2015;62((3)):976.","journal-title":"Hepatology"},{"issue":"3","key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/hep.27700","article-title":"Portal hypertension should not be a contraindication of hepatic resection to treat hepatocellular carcinoma with compensated cirrhosis","volume":"62","author":"Zhong JH","year":"2015","unstructured":"Zhong JH, Li LQ. Portal hypertension should not be a contraindication of hepatic resection to treat hepatocellular carcinoma with compensated cirrhosis. Hepatology. 2015;62((3)):977\u20108.","journal-title":"Hepatology"},{"issue":"2","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/hep.27431","article-title":"Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta\u2010analysis","volume":"61","author":"Berzigotti A","year":"2015","unstructured":"Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta\u2010analysis. Hepatology. 2015;61((2)):526\u201036.","journal-title":"Hepatology"},{"issue":"7","key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1053\/j.gastro.2008.02.091","article-title":"Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma","volume":"134","author":"Ishizawa T","year":"2008","unstructured":"Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et\u00a0al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134((7)):1908\u201016.","journal-title":"Gastroenterology"},{"issue":"6","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/SLA.0b013e3181b977a5","article-title":"Is portal hypertension a contraindication to hepatic resection?","volume":"250","author":"Cucchetti A","year":"2009","unstructured":"Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G, et\u00a0al. Is portal hypertension a contraindication to hepatic resection? Ann Surg. 2009;250((6)):922\u20108.","journal-title":"Ann Surg"},{"issue":"7","key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00268-016-3465-6","article-title":"Comparison of the outcomes of patients with hepatocellular carcinoma and portal hypertension after liver resection versus radiofrequency ablation","volume":"40","author":"Harada N","year":"2016","unstructured":"Harada N, Shirabe K, Maeda T, Kayashima H, Takaki S, Maehara Y. Comparison of the outcomes of patients with hepatocellular carcinoma and portal hypertension after liver resection versus radiofrequency ablation. World J Surg. 2016;40((7)):1709\u201019.","journal-title":"World J Surg"},{"issue":"5","key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.surg.2015.04.002","article-title":"Resection versus ablation in hepatitis B virus\u2212 related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study","volume":"158","author":"Qiu J","year":"2015","unstructured":"Qiu J, Zheng Y, Shen J, Zeng Q\u2010A, Zou R, Liao Y, et\u00a0al. Resection versus ablation in hepatitis B virus\u2212 related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study. Surgery. 2015;158((5)):1235\u201043.","journal-title":"Surgery"},{"issue":"3","key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet JM","year":"1999","unstructured":"Llovet JM, Br\u00fa C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in Liver Disease. 1999;19((3)):329\u201038.","journal-title":"Seminars in Liver Disease"},{"issue":"3","key":"e_1_3_2_15_2","first-page":"554","article-title":"Is portal hypertension due to liver cirrhosis a major factor in the development of portal hypertensive gastropathy?","volume":"91","author":"Bayraktar Y","year":"1996","unstructured":"Bayraktar Y, Balkanci F, Uzunalimoglu B, Gokoz A, Koseoglu T, Batman F, et\u00a0al. Is portal hypertension due to liver cirrhosis a major factor in the development of portal hypertensive gastropathy? Am J Gastroenterol. 1996;91((3)):554\u20108.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"e_1_3_2_16_2","first-page":"295","article-title":"The Italian program on liver\u2010cirrhosis\u2010portal\u2010hypertension","volume":"19","author":"Pagliaro L","year":"1987","unstructured":"Pagliaro L, Spina G. The Italian program on liver\u2010cirrhosis\u2010portal\u2010hypertension. Ital J Gastroenterol. 1987;19((5)):295\u20107.","journal-title":"Ital J Gastroenterol"},{"issue":"2","key":"e_1_3_2_17_2","doi-asserted-by":"crossref","DOI":"10.1097\/AS9.0000000000000057","article-title":"Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma","volume":"2","author":"Li B","year":"2021","unstructured":"Li B, Qiu J, Zheng Y, Shi Y, Zou R, He W, et\u00a0al. Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma. Ann Surg Open. 2021;2((2)):e057.","journal-title":"Ann Surg Open"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1007\/s00330-019-06157-0","article-title":"Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation","volume":"29","author":"Yang Z","year":"2019","unstructured":"Yang Z, Zou R, Zheng Y, Qiu J, Shen J, Liao Y, et\u00a0al. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation. Eur Radiol. 2019;29:5752\u201062.","journal-title":"Eur Radiol"},{"issue":"6","key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/apt.14929","article-title":"Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis","volume":"48","author":"Liu W","year":"2018","unstructured":"Liu W, Zheng Y, He W, Zou R, Qiu J, Shen J, et\u00a0al. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Aliment Pharmacol Ther. 2018;48((6)):671\u201081.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien\u2010Dindo classification of surgical complications: five\u2010year experience","volume":"250","author":"Clavien PA","year":"2009","unstructured":"Clavien PA, Barkun J, De Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et\u00a0al. The Clavien\u2010Dindo classification of surgical complications: five\u2010year experience. Ann Surg. 2009;250((2)):187\u201096.","journal-title":"Ann Surg"},{"issue":"6","key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/bjs.8753","article-title":"Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis","volume":"99","author":"Boleslawski E","year":"2012","unstructured":"Boleslawski E, Petrovai G, Truant S, Dharancy S, Duhamel A, Salleron J, et\u00a0al. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Journal of British Surgery. 2012;99((6)):855\u201063.","journal-title":"Journal of British Surgery"},{"issue":"12","key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/bjs.7672","article-title":"Value of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma","volume":"98","author":"Stremitzer S","year":"2011","unstructured":"Stremitzer S, Tamandl D, Kaczirek K, Maresch J, Abbasov B, Payer B, et\u00a0al. Value of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma. Journal of British Surgery. 2011;98((12)):1752\u20108.","journal-title":"Journal of British Surgery"},{"issue":"4","key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL\u2013EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"European Association for the Study of the Liver & European Organisation for Research and Treatment of Cancer","year":"2012","unstructured":"European Association for the Study of the Liver & European Organisation for Research and Treatment of Cancer . EASL\u2013EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56((4)):908\u201043.","journal-title":"J Hepatol"},{"issue":"4","key":"e_1_3_2_24_2","first-page":"310","article-title":"Expert consensus on clinical diagnosis and treatment of portal hypertension with hepatocellular carcinoma (2022)","volume":"60","author":"Chinese Medical Association","year":"2022","unstructured":"Chinese Medical Association . Expert consensus on clinical diagnosis and treatment of portal hypertension with hepatocellular carcinoma (2022). Zhonghua Wai Ke Za Zhi. 2022;60((4)):310\u201020.","journal-title":"Zhonghua Wai Ke Za Zhi"},{"issue":"3","key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/hep.27702","article-title":"Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta\u2010analysis. More doubts than clarity","volume":"62","author":"Cucchetti A","year":"2015","unstructured":"Cucchetti A, Cescon M, Pinna AD. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta\u2010analysis. More doubts than clarity. Hepatology. 2015;62((3)):976\u20107.","journal-title":"Hepatology"},{"issue":"9","key":"e_1_3_2_26_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108755","article-title":"Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension","volume":"9","author":"Zhong J\u2010H","year":"2014","unstructured":"Zhong J\u2010H, Li H, Xiao N, Ye X\u2010P, Ke Y, Wang Y\u2010Y, et\u00a0al. Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension. PLoS One. 2014;9((9)):e108755.","journal-title":"PLoS One"},{"key":"e_1_3_2_27_2","first-page":"1","article-title":"The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis","volume":"15","author":"He W","year":"2015","unstructured":"He W, Zeng Q, Zheng Y, Chen M, Shen J, Qiu J, et\u00a0al. The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis. BMC Cancer. 2015;15:1\u201011.","journal-title":"BMC Cancer"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1007\/s00464-020-07763-6","article-title":"Safety and feasibility of laparoscopic liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a propensity score\u2010matched study","volume":"35","author":"Zheng J","year":"2021","unstructured":"Zheng J, Feng X, Liang Y, Cai J, Shi Z, Kirih MA, et\u00a0al. Safety and feasibility of laparoscopic liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a propensity score\u2010matched study. Surg Endosc. 2021;35:3267\u201078.","journal-title":"Surg Endosc"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00268-005-0524-9","article-title":"Portal hypertension: contraindication to liver surgery?","volume":"30","author":"Capussotti L","year":"2006","unstructured":"Capussotti L, Ferrero A, Vigan\u00f2 L, Muratore A, Polastri R, Bouzari H. Portal hypertension: contraindication to liver surgery? World J Surg. 2006;30:992\u20109.","journal-title":"World J Surg"},{"issue":"46","key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.3748\/wjg.v17.i46.5083","article-title":"Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated?","volume":"17","author":"Ruzzenente A","year":"2011","unstructured":"Ruzzenente A, Valdegamberi A, Campagnaro T, Conci S, Pachera S, Iacono C, et\u00a0al. Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated? World J Gastroenterol. 2011;17((46)):5083.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ueg2.12188","article-title":"Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"10","author":"M\u00fcller L","year":"2022","unstructured":"M\u00fcller L, Hahn F, M\u00e4hringer\u2010Kunz A, Stoehr F, Gairing SJ, Foerster F, et\u00a0al. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United European Gastroenterol J. 2022;10((1)):41\u201053.","journal-title":"United European Gastroenterol J"},{"issue":"3","key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000521665","article-title":"Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF trial)","volume":"11","author":"Takayama T","year":"2022","unstructured":"Takayama T, Hasegawa K, Izumi N, Kudo M, Shimada M, Yamanaka N, et\u00a0al. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF trial). Liver cancer. 2022;11((3)):209\u201018.","journal-title":"Liver cancer"},{"issue":"4","key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2012.42.9936","article-title":"Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial","volume":"31","author":"Peng Z\u2010W","year":"2013","unstructured":"Peng Z\u2010W, Zhang Y\u2010J, Chen M\u2010S, Xu L, Liang H\u2010H, Lin X\u2010J, et\u00a0al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31((4)):426\u201032.","journal-title":"J Clin Oncol"},{"issue":"43","key":"e_1_3_2_34_2","first-page":"41","article-title":"Resection of hepatocellular carcinoma: a European experience on 328 cases","volume":"49","author":"Belghiti J","year":"2002","unstructured":"Belghiti J, Regimbeau J, Durand F, Kianmanesh A, Dondero F, Terris B, et\u00a0al. Resection of hepatocellular carcinoma: a European experience on 328 cases. Hepatogastroenterology. 2002;49((43)):41\u20106.","journal-title":"Hepatogastroenterology"},{"issue":"4","key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/SLA.0000000000000917","article-title":"Differences in surgical outcomes between hepatitis B\u2010and hepatitis C\u2013related hepatocellular carcinoma: a retrospective analysis of a single North American center","volume":"260","author":"Franssen B","year":"2014","unstructured":"Franssen B, Alshebeeb K, Tabrizian P, Marti J, Pierobon ES, Lubezky N, et\u00a0al. Differences in surgical outcomes between hepatitis B\u2010and hepatitis C\u2013related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann Surg. 2014;260((4)):650\u20108.","journal-title":"Ann Surg"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1002\/cac2.12614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:47:57Z","timestamp":1773823677000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1002\/cac2.12614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1002\/cac2.12614"],"URL":"https:\/\/doi.org\/10.1002\/cac2.12614","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]},"assertion":[{"value":"2024-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}